Oldfield Partners Llp Has Lowered By $2.89 Million Its Guess (TKC) Position; Aclaris Therapeutics (ACRS) Had 5 Bullish Analysts

September 4, 2017 - By Winifred Garcia

Oldfield Partners Llp decreased Guess Inc (TKC) stake by 15.17% reported in 2016Q4 SEC filing. Oldfield Partners Llp sold 481,182 shares as Guess Inc (TKC)’s stock declined 1.71%. The Oldfield Partners Llp holds 2.69M shares with $18.57M value, down from 3.17M last quarter. Guess Inc now has $8.49 billion valuation. The stock increased 0.21% or $0.02 on September 1, reaching $9.48. About shares traded. Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) has declined 9.06% since September 4, 2016 and is downtrending. It has underperformed by 25.76% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 13 analyst reports since November 2, 2015 according to SRatingsIntel. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has “Buy” rating given on Monday, September 19 by Jefferies. Leerink Swann initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Tuesday, November 29. Leerink Swann has “Outperform” rating and $54 target. The rating was initiated by Guggenheim on Friday, June 10 with “Buy”. Jefferies maintained Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Friday, July 28. Jefferies has “Buy” rating and $3600 target. JMP Securities initiated the stock with “Market Perform” rating in Friday, September 30 report. Jefferies initiated the shares of ACRS in report on Monday, November 2 with “Buy” rating. The rating was maintained by Jefferies on Friday, August 12 with “Buy”. The rating was initiated by Citigroup with “Buy” on Monday, November 2. The rating was initiated by William Blair with “Outperform” on Monday, November 2. The firm has “Buy” rating given on Thursday, August 31 by Jefferies. See Aclaris Therapeutics Inc (NASDAQ:ACRS) latest ratings:

31/08/2017 Broker: Jefferies Rating: Buy New Target: $36.0 Maintain
09/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0000 Maintain
28/07/2017 Broker: Jefferies Rating: Buy New Target: $36.0000 Maintain
26/06/2017 Broker: Jefferies Rating: Buy New Target: $36.0000 Maintain

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The company has market cap of $773.91 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Firm is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

The stock decreased 0.50% or $0.13 on September 1, reaching $25.8. About 112,785 shares traded. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 25.57% since September 4, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Among 3 analysts covering Turkcell (NYSE:TKC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Turkcell had 4 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Thursday, September 17. The firm has “Neutral” rating given on Thursday, September 3 by Bank of America. The stock has “Neutral” rating by JP Morgan on Wednesday, April 6. The firm has “Buy” rating by Deutsche Bank given on Thursday, January 5.